Pharmaceutical Business review

Proteonomix names new board member

Mr Byle is presently vice-president of technology for Dockwise, a public, international company, where he is in charge of its R&D program and intellectual property portfolio.

Michael Cohen, CEO of Proteonomix, said: “We welcome Steven to our board of directors. His extensive background both in intellectual property and corporate development shall enhance our company’s growth and development in its commercialization stage.”

Exit mobile version